The FDA agreed to speed its review of a Roche drug the developer says could be the first oral high-efficacy therapy approved ...
Higher blood levels of a marker of nerve damage are associated with lower daily activity in people with progressive forms of ...
InvestorsHub on MSN
Roche’s fenebrutinib receives FDA priority review for relapsing and primary progressive multiple sclerosis
The FDA has accepted fenebrutinib for priority review across two forms of multiple sclerosis following three Phase III ...
19hon MSN
Ms Rachel builds sprawling media empire while shelling out thousands to progressive candidates
Ms. Rachel has donated thousands to progressive political candidates as her popular children's education brand expanded into ...
Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent ...
The National Multiple Sclerosis Society today launched the Campaign to End MS, a five-year campaign to raise $1 billion to ...
The National Multiple Sclerosis Society marked a historic moment today, launching the Campaign to End MS with a day of events ...
Supported by phase 3 FENhance 1, FENhance 2, and FENtrepid trial results, oral fenebrutinib reduced relapse rates and showed numerical benefits in delaying disability progression across the MS ...
The FDA has granted priority review to Roche’s New Drug Application for fenebrutinib in relapsing and primary progressive MS.
Roche Holding (SWX:ROP) received FDA acceptance of its New Drug Application for fenebrutinib in multiple sclerosis under ...
One of the most persistent questions in multiple sclerosis research has been whether people who inherit a family predisposition to the disease also face a harsher course once the disease appears. A ...
The NDA for fenebrutinib is supported by three positive Phase III studies: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results